Immuron (ASX:IMC), (NASDAQ:IMRN) is an Australian-based biopharmaceutical company focusing on the research, development, and commercialization of oral immunotherapy products. Immuron's main projects aim to tackle various gastrointestinal and liver diseases, leveraging its unique platform technology to produce oral immune-modulating polyclonal antibodies. Among its leading products is Travelan, an over-the-counter product for the prevention of travelers' diarrhea, and a pipeline of pre-clinical candidates targeting severe liver diseases, including NASH (Non-alcoholic steatohepatitis). Immuron's objective is to harness its proprietary technology to create therapies that improve health outcomes for patients worldwide dealing with immune-mediated and infectious diseases, constantly striving to expand its product portfolio and research capabilities to address unmet medical needs.